ArticleOncotarget2017
Diagnostic and prognostic value of serum periostin in patients with non-small cell lung cancer.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Prognostic Value of Periostin Expression in Non-Small Cell Lung Cancer: A Meta-Analysis.Medical science monitor : international medical journal of experimental and clinical research · 2022Pooled it
- Calumenin, A Calcium-Binding Modulatory Protein, Effective in Pathological Calcifications and Cancers, With Therapeutic Application Promise.FASEB bioAdvances · 2025Review
- Periostin from Tumor Stromal Cells Might Be Associated with Malignant Progression of Colorectal Cancer via Smad2/3.Cancers · 2025Article
- Biological implications of decoding the extracellular matrix of vulva cancer.Oncology reports · 2025Review
- Correlation between Periostin Expression and Pro-Angiogenic Factors in Non-Small-Cell Lung Carcinoma.Cells · 2024Article
- Current evidence regarding the cellular mechanisms associated with cancer progression due to cardiovascular diseases.Journal of translational medicine · 2024Review
- Periostin secreted by cancer-associated fibroblasts promotes cancer progression and drug resistance in non-small cell lung cancer.Journal of molecular medicine (Berlin, Germany) · 2023Article
- Association between serum periostin levels and the severity of arsenic-induced skin lesions.PloS one · 2023Article
- Periostin: biology and function in cancer.Cancer cell international · 2022Review
- Prognostic utility of the ovarian cancer secretome: a systematic investigation.Archives of gynecology and obstetrics · 2022Review
- Review
- Diagnostic value of periostin in lung cancer-related malignant pleural effusion.Journal of clinical laboratory analysis · 2022Article
- Periostin secreted by activated fibroblasts in idiopathic pulmonary fibrosis promotes tumorigenesis of non-small cell lung cancer.Scientific reports · 2021Article
- Serum total periostin is an independent marker of overall survival in bone metastases of lung adenocarcinoma.Journal of bone oncology · 2021Article
- Pathological Roles and Clinical Usefulness of Periostin in Type 2 Inflammation and Pulmonary Fibrosis.Biomolecules · 2021Review
- Biomarkers for Comorbidities Modulate the Activity of T-Cells in COPD.International journal of molecular sciences · 2021Article
- Proteomic Analysis of the Air-Way Fluid in Lung Cancer. Detection of Periostin in Bronchoalveolar Lavage (BAL).Frontiers in oncology · 2020Article
- Periostin serves an important role in the pathogenesis of oral squamous cell carcinoma.Oncology letters · 2019Article
- Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer.Cancer science · 2018Article
- Periostin is a negative prognostic factor and promotes cancer cell proliferation in non-small cell lung cancer.Oncotarget · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The periostin protein is expressed in a variety of human malignancies. The aim of this study was to explore the diagnostic and prognostic value of serum periostin levels in patients with non-small cell lung cancer (NSCLC). We measured serum periostin levels by ELISA in 296 NSCLC patients, 120 benign lung diseases (BLD) patients and 160 healthy controls. The levels of serum periostin in NSCLC patients were significantly elevated compared with those in healthy controls (P < 0.001) and BLD patients (P < 0.001). Using a cutoff value of 30.87 ng/ml, the sensitivity and specificity of periostin in differentiating between NSCLC patients and BLD patients, and between NSCLC patients and healthy controls was, 48.6 and 91.7%, and 51.4 and 97.5%, respectively. Kaplan-Meier log rank analysis revealed that the higher serum periostin levels group had a poorer progression-free survival (PFS) and overall survival (OS) compared with lower periostin group (P = 0.024, P = 0.015, respectively). Further univariate and multivariate Cox regression analysis showed that serum periostin was an independent risk factor of prognosis of NSCLC patients. In conclusion, our study suggests that serum periostin could be considered as a diagnostic and prognostic marker for NSCLC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.